Poland· PL-100529613
Teizeild
A teplizumab product containing teplizumab, registered in Poland by Sanofi Winthrop Industrie. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Teplizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC A10XX01 (teplizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Teplizumab · ATC A10XX01
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Teplizumab
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Poland (PL)
- ATC code
- A10XX01
- ATC class
- Teplizumab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05909991589677
- gtin05909991589684
- gtin05909991589691
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Teplizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTEIZEILDSanofi Winthrop Industrie, Gentilly
- SwitzerlandTeizeild 2 mg/2 mL, solution à diluer pour perfusionSanofi-Aventis (Suisse) SA
- FinlandTeizeildSanofi Winthrop Industrie
- IrelandTeizeild 1 mg/mL concentrate for solution for infusionSanofi Winthrop Industrie
- IcelandTeizeildSanofi Winthrop Industrie
- NorwayTeizeildSanofi Winthrop Industrie
- BelgiumTeizeild 1 mg/mlSanofi Winthrop Industrie
- SwedenTeizeild 1 mg/ml Koncentrat till infusionsvätska, lösningSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Teizeild
- Liechtenstein · Teizeild
- Norway · Teizeild
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9bad8da-3f67-4dc5-aeeb-1787c5198a67 GET /v1/drugs/e9bad8da-3f67-4dc5-aeeb-1787c5198a67?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "2 mg/2 ml",
"packaging": "05909991589677 ¦ Rp ¦ EU/1/25/1998/001 ¦ 164940\n1 fiol. \n05909991589684 ¦ Rp ¦ EU/1/25/1998/002 ¦ 164941\n10 fiol. \n05909991589691 ¦ Rp ¦ EU/1/25/1998/003 ¦ 164942\n14 fiol.",
"substance": "Teplizumab 2 mg/2 ml",
"common_name": "Teplizumab",
"pl_product_id": "100529613",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about teplizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.